In the context of colorectal cancer, NK cell-targeted therapies have shown multi-dimensional advancement: CAR-NK cells targeting NKG2D (NCT05213195) noted 100% control of disease following local infusion (32); CF33-hNIS oncolytic virus monotherapy or pembrolizumab combination considerably increased NK activity, achieving an 86% DCR (32, 33); While the CEA-DC vaccine indirectly activates NK cells, a Phase II clinical trial for a dendritic cell vaccine in MSI-type CRC is underway, but currently has good safety and tolerability (NCT01885702) (34). Here, KLRK1 is linked to colorectal cancer.